Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer by Cellbion for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What's Your Reaction?
